ImmunityBio (IBRX) Other Non-Current Assets (2014 - 2026)

ImmunityBio (IBRX) has reported Other Non-Current Assets for 13 consecutive years, with $378000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $378000.0; the TTM figure through Mar 2026 stood at $378000.0 (changed 0.0% YoY), while the FY2025 annual figure was $4.5 million, up 1.82% from the prior year.
• Other Non-Current Assets declined to $378000.0 in Q1 2026 per IBRX's latest filing, from $4.5 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $6.5 million in Q1 2022 and bottomed at $378000.0 in Q1 2025.
• Historically, Other Non-Current Assets has averaged $3.6 million across 5 years, with a median of $3.8 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 3518.44% — and 2025, when it sank 86.15%.
• ImmunityBio's Other Non-Current Assets stood at $4.9 million in 2022, then plunged by 40.74% to $2.9 million in 2023, then soared by 54.48% to $4.4 million in 2024, then increased by 1.82% to $4.5 million in 2025, then sank by 91.66% to $378000.0 in 2026.
• Business Quant data shows IBRX's Other Non-Current Assets at $378000.0 in Q1 2026, $4.5 million in Q4 2025, and $4.5 million in Q3 2025.